2014年　業績集

  1. Suzuki T, Kusumoto S, Iida S, Tada T, Mori F. Amelanotic malignant melanoma of unknown primary origin metastasizing to the bone marrow: case report and review of the literature. Int Med. 2014;53: 325-328.
  2. Mori F, Ishida T, Ito A, Sato F, Masaki A, Narita T, Suzuki S, Yamada T, Takino H, Ri M, Kusumoto S, Komatsu H, Hishizawa M, Imada K, Takaori-Kondo A, Niimi A, Ueda R, Inagaki H, Iida S. Anti-tumor effect of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model. Eur J Hematol 2014; 92: 219-228.
  3. Narita T, Ishida T, Masaki A, Suzuki S, Ito A, Mori F, Yamada T, Ri M, Kusumoto S, Komatsu H, Miyazaki Y, Takatsuka Y, Utsunomiya A, Niimi A, Iida S, Ueda R. HTLV-1 bZIP factor specific T cell response in ATL patients after allogeneic hematopoietic stem cell transplantation. J Immunol 2014;192: 940-947.
  4. Suzuki T, Muto N, Bando M, Itoh Y, Masaki A, Ri M, Ota Y, Nakagawa H, Iida S, Shirafuge K, Miyata N. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. Chem Med Chem 2014; 9: 657-664.
  5. Zwick C, Held G, Auth M, Bernal-Mizrachi L, Roback JD, Sunay S, Iida S, Kuroda Y, Sakai A, Ziepert M, Ueda R, Pfreundscuh M, Preuss K-D. Over one third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal-dominantly inherited risk factor for MGUS/MM. Int J Cancer 2014; 135: 934-938.
  6. Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K, Sahashi T, Kuroda J, Ogura H, Uegaki S, Yoshida T, Mori Y, Sawada H, Watanabe S, Sugiura H, Endo Y, Yoshimoto N, Toyama T, Iida S, Yamada K, Kimura K, Wakita A. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracyclin-treated patients. J Cancer 2014; 5(5): 390-397.
  7. Chinen Y, Kuroda J, Shimura Y, Nagoshi H, Kiyota M, Yamamoto-Sugitani M, Mizutani S, Sakamoto M, Ri M, Kawata E, Kobayashi T, Matsumoto Y, Horiike S, Iida S, Taniwaki M. 3-phosphoinositide-dependent protein kinase 1 (PDPK1) is a crucial cell signaling mediator in multiple myeloma. Cancer Res 2014; 74: 7418-7429.
  8. Yoshida T, Ishii G, Goto K, Neri S, Hashimoto H, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Iida S, Niimi A, Nagai K, Ohe Y, Ochiai A. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res 2014;21(3): 642-651.
  9. Suzuki T, Kusumoto S, Masaki A, Ishida T, Inagaki H, Iida S, Mori F. CD30-positive primary bone marrow lymphoma mimicking Hodgkin lymphoma. Int J Hematol 2014;101: 109-111.
  10. Ogura M*, Ishida T*, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. (*equally contributed)
  11. Nakano N, Kusumoto S, Tanaka Y, Ishida T, Takeuchi S, Takatsuka Y, Akinaga S, Mizokami M, Ueda R, Utsunomiya A. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2014 Mar;44(3):354-7.
  12. Xia H, Yamada S, Aoyama M, Sato F, Masaki A, Ge Y, Ri M, Ishida T, Ueda R, Utsunomiya A, Asai K, Inagaki H. Prognostic impact of miR-145 down-regulation in adult T-cell leukemia/ lymphoma. Hum Pathol. 2014 Jun;45(6):1192-8.
  13. Kikuchi M, Senoo K, Wakita A: Two Cases of Exertional Headache with Cerebral Abnormalities. Jpn Soc Hospital General Medicine. 7; 15-18: 2014.
  14. Tsuboi K, Yamamoto H. Clinical course of patients with Fabry disease who were switched from agalsidase betato agalsidase alfa. Genetics in Medicine 2014; Oct;16(10): 766-72.
  15. Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT, Feng H., BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia. 2014 May;28(5):1145-8.
  16. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CR, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look AT, Mitsiades C, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS. Targeting transcriptional dependencies in cancer using a covalent CDK7 inhibitor. Nature, 2014 Jul 31;511(7511):616-20.
  17. Mok MM, Du L, Wang CQ, Tergaonkar V, Liu TC, Yin SK, Sanda T, Yeoh AE, Osato M, RUNX1 point mutations potentially identify a subset of early immature T-cell acute lymphoblastic leukaemia that may originate from differentiated T-cells. Genes. 2014 Jul 15;545(1):111-6.
  18. Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N. The Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. Gastroenterology. 2014 Jul 3. pii: S0016-5085(14)00852-X.
  19. Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014 Sep 30;5(18):8737-49.
  20. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014 Dec 12;346(6215):1373-7.